IndraLab

Statements

Ruxolitinib inhibits mutated JAK1. 2 / 2
| 2
reach
"As expected, Ruxolitinib was also efficient to inhibit JAK1 mutants, with an efficacy of = ~ 90% at 1 muM in three different hepatocellular cell lines (unpublished results)."
26188635
reach
"To detect the sensitivity of JAK1 mutations to inhibitor, we examined whether ruxolitinib as an inhibitor for JAK1/2 could inhibit the activation of JAK1 mutants."
28410228